Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study

Puneet Jain,1 Paul T Finger,1 Maria Fili,2 Bertil Damato,3 Sarah E Coupland,4 Heinrich Heimann,4 Nihal Kenawy,5 Niels J Brouwer,6 Marina Marinkovic,6 Sjoerd G Van Duinen,6 Jean Pierre Caujolle,7 Celia Maschi,7 Stefan Seregard,2 David Pelayes,8 Martin Folgar,8 Yacoub A Yousef,9 Hatem Krema,10 Brenda Gallie,10 Alberto Calle-Vasquez,11 American Joint Committee on Cancer Ophthalmic Oncology Task Force

ABSTRACT
Background To relate conjunctival melanoma characteristics to local control.
Methods Retrospective, registry-based interventional study with data gathered from 10 ophthalmic oncology centres from 9 countries on 4 continents. Conjunctival melanoma patients diagnosed between January 2001 and December 2013 were enrolled in the study. Primary treatments included local excision, excision with cryotherapy and exenteration. Adjuvant treatments included topical chemotherapy, brachytherapy, proton and external beam radiotherapy (EBRT). Cumulative 5-year and 10-year Kaplan-Meier local recurrence rates were related to clinical and pathological T-categories of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system.
Results 288 patients had a mean initial age of 59.7 ±16.8 years. Clinical T-categories (cT) were cT1 (n=218, 75.7%), cT2 (n=34, 11.8%), cT3 (n=15, 5.2%), cTx (n=21, 7.3%) with no cT4. Primary treatment included local excision (n=161/288, 55.9%) followed by excision biopsy with cryotherapy (n=108/288, 37.5%) and exenteration (n=5/288, 1.7%). Adjuvant therapies included topical mitomycin (n=107/288, 37.1%), plaque-brachytherapy (n=55/288, 19.1%), proton-beam (n=36/288, 13.5%), topical interferon (n=20/288, 6.9%) and EBRT (n=15/288, 5.2%). Secondary exenteration was performed (n=11/283, 3.9%). Local recurrence was noted in 19.1% (median=3.6 years). Cumulative local recurrence was 5.4% (3.2–8.9%), 19.3% (14.4–25.5%) and 36.9% (26.5–49.9%) at 1, 5 and 10 years, respectively. cT3 and cT2 tumors were twice as likely to recur than cT1 tumors, but only cT3 had statistically significantly greater risk of local recurrence than cT1 (p=0.013). Factors such as tumour ulceration, plica or caruncle involvement and tumour thickness were not significantly associated with an increased risk of local recurrence.
Conclusion This multicentre international study showed that eighth edition of AJCC tumour staging was related to the risk of local recurrence of conjunctival melanoma after treatment. The 10-year cumulative local recurrence remains high despite current management.

INTRODUCTION
Conjunctival melanoma is rare, comprising <1% of all (whole body) melanomas.2 The incidence is less than 1 case per million population, but it is on the rise.2–4 Tumour staging is widely performed according to the eighth edition of the American Joint Committee on Cancer (AJCC) staging system.5 6

The most common treatment is wide excision with cryotherapy.2–4 Over the last several decades, topical chemotherapy and/or radiotherapy have been applied both as primary therapy and adjuvant therapy.7–10 Despite close surveillance and intensive therapy at subspecialty centres, the 10-year tumour recurrence rates are reported to be as high as 69%,1 11–16 Reported risk factors for local recurrence include non-bulbar tumour location, higher AJCC stage, increased tumour thickness and ulceration.11–16

The last decade has seen a significant growth towards eye cancer research collaboration. Multicentre studies able to accumulate large cohorts of patients with rare eye tumours, amenable to statistically significant analysis in terms of clinical spectrum, management and treatment outcomes include: uveal melanoma, ocular adnexal lymphoma, iris melanoma, eyelid lymphoma to name a few.17–25 These efforts have improved, evidence-based understanding of the natural history of the tumours and standards of patient care. Moreover, collaborative data sharing also help in refining and validating the tumour staging systems.5 26

Herein, we present the first multicentre, international, registry-based study of tumour characteristics and control as well as the cumulative 5-year and 10-year local recurrence rates in patients with conjunctival melanoma. This database has been used to validate/assess the eighth edition of the AJCC staging manual for conjunctival melanoma.5

METHODS
Conjunctival melanoma registry
The AJCC Ophthalmic Oncology Task Force created and used an internet-based registry to share data from 10 ophthalmic oncology centres in nine countries from four continents.7 This study
conformed to the tenets of the Declaration of Helsinki and the United States of America Health Insurance Portability and Accountability Act of 1996. Internal Review Board approvals were obtained by each of the participating centres for retrospective chart review, data-pooling, analysis and publication.

Patient enrolment
This multicentre international study included patients diagnosed with conjunctival melanoma between 1 January 2001 and 31 December 2013. Open enrolment of subspecialty centres occurred during The First Eye Cancer Working Day held at the Curie Institute, Paris, France, in 2015.27

Data collection and security
Data collection was retrospective. Each of the participating centres had separate user accounts (distinct usernames with passwords) ensuring limited registry access. The digital representation of the patients was by means of unique identification numbers; therefore, no personal patient identifiers existed. Secure socket layer encryption and record locking ensured data sanctity.5

Ophthalmic examination
Demographic data included patient age and sex. Ophthalmologic examinations were inclusive of, but not limited to slit-lamp biomicroscopy with photography, gonioscopic photography, dilated fundus examination and high-frequency anterior segment ultrasound imaging to rule out intra-ocular invasion. Orbital imaging in the form of either CT or MRI was performed. All the participating centres performed the examinations as per their usual standards and practices.

Regional and systemic examination
Regional examination was limited to clinical assessment of the pre-auricular, post-auricular, submandibular and anterior cervical lymph nodes. Systemic examination used radiographic imaging including CT, MRI and whole-body positron emission tomography/computed tomography (PET/CT).28 29

Tumour staging
Tumour staging was performed according to the eighth edition of the AJCC staging system for conjunctival melanoma, as shown in table 1.

Treatment
Local treatments represented the standards of care at each subspeciality ophthalmic oncology centre. The primary treatment included, but was not limited to, wide local excision, excision biopsy with cryotherapy, enucleation, exenteration. Alternative or adjuvant treatment included topical chemotherapy, plaque brachytherapy, proton beam therapy and external beam radiotherapy (EBRT). Topical chemotherapeutic agents included mitomycin-C (MMC, 0.02% or 0.04%), topical interferon-alfa2b (IFNα2b, 1 million IU/ml) and 5-fluorouracil (5-FU, 1%). Plaque brachytherapy was with either with ruthenium-106 or strontium-90 plaques.

Local tumour recurrence
Recurrence was defined by each clinical centre. The data field entry was ‘local recurrence’, and details were recorded as type, date and site of recurrence.

Statistical analysis
Continuous variables were expressed as mean with SD or median with IQR, and group-wise comparisons were made using the Student’s t-test for parametric variables or Wilcoxon rank-sum test for non-parametric variables. Categorical variables were expressed as proportions, and the χ² test or Fisher’s exact test was used to analyse group differences across categorical variables.

Separate survival analysis was performed and Kaplan-Meier (K-M) curves were plotted to depict cumulative rates of local recurrence at various time points. Time for recurrence was defined as interval between treatment and time of local tumour recurrence. Comparison between the rates of local recurrence between different subgroups was analysed using the logrank test.

The survival probability for local recurrence was assessed using the Cox proportional hazards models and displayed using HRs. Covariates used for adjusting HRs were those with a p value <0.1 in univariate models and those that have been shown to influence local recurrence in previous studies.

Data were entered in the online data registry and maintained in Microsoft Access. Data were analysed using STATA (version 12.1, I/C, Fort Worth, Texas, USA) statistical analysis software package, and p<0.05 was considered statistically significant.

RESULTS
The registry collected information on 288 eyes of 288 patients with conjunctival melanoma. The mean (±SD) age at presentation was 59.7±16.8 years (median=49.4 years, IQR=36–71 years, range=15–95 years). With regards to patients, 51% were men (n=147/288) and 53% had right eye involvement (n=154/288). Race and ethnicity data were not collected.

Clinical features
The primary tumour characteristics were identified in 92.7% eyes (n=267/288).

Tumour location
The tumour was identified as bulbar in 83.5% eyes (n=223/267) and non-bulbar in 16.5% eyes (n=44/267).

Tumour extent
 Conjunctival zones of tumour margin were listed in postero-anterior order, with cornea being the posterior limit and eyelid skin being the anterior limit (figure 1). The posterior margin of tumour was limited to the bulbar conjunctiva in 24.3% (n=65/267) followed by cornea in 20.2% (n=54/267), limbus 15.4% (n=41/267), fornix in 2.6% (n=7/267), caruncle in 2% (n=5/267), palpebral conjunctiva in 1.5% (n=4/267), lid margin in 0.7% (n=2/267) and palpebral conjunctiva in 0.3% (n=1/267). The anterior margin of the tumour was limited to bulbar conjunctiva in 45.7% eyes (n=122/267) followed by the limbus in 5.6% eyes (n=15/267), cornea in 4.9% (n=13/267), fornix in 3% (n=8/267), tarsal conjunctiva in 2.6% (n=7/267), lid margin in 1.5% (n=4/267), caruncle in 1% (n=3/267) and eyelid skin in 1% (n=3/267). Overall, caruncular involvement was seen in 11.1% eyes (n=32/288), plica in 10.8% eyes (n=31/287) and eyelid in 3.5% eyes (n=10/288).

Tumour nodularity
Nodular component to the tumour was seen in 72.3% eyes (n=193/267) and extended for a mean of 2 clock hours (median=2 clock hours, range=1–10 clock hours, SD=2.4).

Tumour pigmentation
The tumour colour was documented in 123 eyes. Dark brown (n=47/123, 38.2%) was most common followed by light brown (n=27/123, 21.9%), pink (n=23/123, 18.7%), black (n=11/123, 9.0%) and blue (n=11/123, 8.9%).
8.9%), red (n=8/123, 6.5%), grey (n=3/123, 2.4%) and two each were defined as yellow or white in colour.

Tumour ulceration
Tumour surface ulceration was noted in 9.7% eyes (n=14/143).

Acquired melanosis
Acquired melanosis was noted in 31.9% eyes (n=92/288); these tumours were most commonly light brown in colour (n=41/92, 44.6%) followed by dark brown (n=13/92, 14.1%) and rarely pink (n=3/92, 3.2%). The melanosis extended for 2 clock hours (mean=2.03±3.8 clock hours, median=4 clock hours, range=1–10 clock hours) and 78.2% (n=72/92) had a nodular component.

Tumour invasion
Eyelid invasion was seen in 3.5% eyes (n=10/288) and orbital invasion in 1.4% eyes (n=4/288). Invasion into the globe or paranasal sinuses was not noted.

Pathological features
Specimens for histopathological examination were available in 271 eyes (n=271/288, 94%). The mean diameter of the melanoma was 7.3±4.4 mm (median=6.25 mm, IQR=4–10 mm, range=0.9–27 mm) while the mean thickness was 1.9±2.2 mm (median=1 mm, IQR=0.6–2.5 mm, range=0.2–16 mm). Maximum tumour thickness was >2 mm in 27% (n=54/201) and ≤2 mm in 73% (n=147/201). Lymphatic invasion was noted in 6.8% (n=10/148).

Nodal and systemic spread
Lymph node involvement at presentation was noted in 13 cases (n=13/288, 4.5%), involving ipsilateral cervical (n=7/13, 53.8%), pre-auricular (n=7/13, 53.8%), post-auricular (n=2/13, 15.3%), submandibular nodes (n=2/13, 15.3%) and uncategorised in four cases.

At presentation, systemic metastasis was seen in five patients (n=5/288, 1.7%) with three patients having lung and two having...
liver metastasis. Over a median follow-up of 4.3 years (IQR=2.9–6 years), 24 patients (n=24/283, 8.5%) developed metastasis. In this group, liver was the most common site (n=11/24, 45.8%), followed by lungs (n=9/24, 37.5%), brain (n=3/24, 12.5%), bone (n=2/24, 8.3%) and one each (n=1/24, 4.2%) of parotid gland, skin, peritoneum and bladder. Metastatic sites were undocumented in three patients (n=3/24, 12.5%). Multi-organ metastases were seen in 10 patients (n=10/24, 41.7%).

**TNM classification**

The eighth edition of the AJCC tumor node metastasis (TNM) conjunctival melanoma classification was employed. The clinical T-categories (cT) were cT1 (n=218, 75.7%), followed by cT2 (n=34, 11.8%), cT3 (n=15, 5.2%) and cTx (n=21, 7.3%), as shown in table 2. The pathological T-categories (pT) were pTis (n=43, 14.9%), pT1 (n=169, 58.7%), pT2 (n=33, 11.5%), pT3 (n=12, 4.2%) and pTx (n=31, 10.8%), as shown in table 3. There were no T4 tumours in this study.

Nodal status at presentation was N0 (n=209, 72.6%) followed by N1 (n=13, 4.5%) and Nx (n=66, 22.9%). Metastasis classification at presentation was M0 (n=216, 75%), M1 (n=5, 1.7%).

**Treatment**

Primary treatment in order of frequency used included wide local excision (n=161/288, 55.9%) followed by excision biopsy with cryotherapy (n=108/288, 37.5%), exenteration (n=5/288, 1.7%), topical MMC (n=2/288, 1%), topical IFNα2b (n=2/288, 1%) and one patient each underwent plaque brachytherapy and enucleation. Primary treatment was not specified in eight patients.

Adjuvant treatment included topical MMC (n=107/288, 37.1%), plaque brachytherapy (n=55/288, 19.1%) including strontium (n=31/288, 10.7%) or ruthenium brachytherapy (n=8/288, 2.7%), proton beam therapy (n=36/288, 13.5%), topical IFNα2b (n=20/288, 6.9%), EBRT (n=15/288, 5.2%) and two patients received topical 5-FU. Overall, 199 eyes (n=199/288, 69.1%) received adjuvant therapy. Eleven patients eventually underwent secondary exenteration (n=11/282, 3.9%). The median follow-up time was 4.4 years (IQR=2.3–6.9 years; range=1 month–14.3 years).

**Local recurrence**

Fifty-five eyes (n=55/288, 19.1%) showed local recurrence at a median of 3.6 years (IQR=1.8–5.7 years, range=0.1–14.3 years). The cumulative local recurrence rates based on clinical AJCC stage are shown in Table 2.

**Table 2** Cumulative local recurrence rates based on clinical AJCC stage

<table>
<thead>
<tr>
<th>Clinical T-category (cT)</th>
<th>No. patients</th>
<th>No. recurred (%)</th>
<th>Cumulative % of local recurrence (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 year</td>
</tr>
<tr>
<td>Tx</td>
<td>12</td>
<td>2 (17)</td>
<td>10.8% (3% to 37%)</td>
</tr>
<tr>
<td>T1*</td>
<td>28</td>
<td>11 (39)</td>
<td>16.2% (6% to 37%)</td>
</tr>
<tr>
<td>T1a</td>
<td>115</td>
<td>21 (17)</td>
<td>3.7% (1% to 9%)</td>
</tr>
<tr>
<td>T1b</td>
<td>62</td>
<td>9 (14)</td>
<td>3.4% (0.8% to 13%)</td>
</tr>
<tr>
<td>T1c</td>
<td>8</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>T1d</td>
<td>5</td>
<td>1 (50)</td>
<td>50% (9% to 99%)</td>
</tr>
<tr>
<td>T2*</td>
<td>5</td>
<td>2 (40)</td>
<td>0</td>
</tr>
<tr>
<td>T2a</td>
<td>8</td>
<td>1 (12.5)</td>
<td>14.3% (2% to 66%)</td>
</tr>
<tr>
<td>T2b</td>
<td>5</td>
<td>1 (20)</td>
<td>20% (3% to 79%)</td>
</tr>
<tr>
<td>T2c</td>
<td>8</td>
<td>2 (25)</td>
<td>16 (2% to 73%)</td>
</tr>
<tr>
<td>T2d</td>
<td>7</td>
<td>1 (14)</td>
<td>0</td>
</tr>
<tr>
<td>T3a</td>
<td>1</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>T3b</td>
<td>10</td>
<td>3 (30)</td>
<td>12.5% (2% to 61%)</td>
</tr>
<tr>
<td>T3c</td>
<td>4</td>
<td>1 (25)</td>
<td>0</td>
</tr>
</tbody>
</table>

*Subgroup data not available.

AJCC, American Joint Committee on Cancer; em dash, not calculable.

**Table 3** Cumulative local recurrence rates based on pathological AJCC stage

<table>
<thead>
<tr>
<th>Pathology T-category (pT)</th>
<th>No. patients</th>
<th>No. recurred (%)</th>
<th>Cumulative % of local recurrence (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 year</td>
</tr>
<tr>
<td>Tx</td>
<td>31</td>
<td>5 (16)</td>
<td>15.3% (6% to 35.7%)</td>
</tr>
<tr>
<td>Tis</td>
<td>43</td>
<td>8 (17)</td>
<td>12.4% (4.8% to 29.7%)</td>
</tr>
<tr>
<td>T1a</td>
<td>123</td>
<td>27 (22)</td>
<td>5.2% (2.4% to 11.3%)</td>
</tr>
<tr>
<td>T1b</td>
<td>46</td>
<td>6 (13)</td>
<td>7.2% (2.4% to 20.6%)</td>
</tr>
<tr>
<td>T2a</td>
<td>12</td>
<td>2 (17)</td>
<td>21.4% (55.5% to 63.9%)</td>
</tr>
<tr>
<td>T2b</td>
<td>21</td>
<td>5 (24)</td>
<td>5.3% (0.7% to 31.2%)</td>
</tr>
<tr>
<td>T3a</td>
<td>1</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>T3b</td>
<td>6</td>
<td>1 (17)</td>
<td>0</td>
</tr>
<tr>
<td>T3c</td>
<td>5</td>
<td>1 (20)</td>
<td>0</td>
</tr>
</tbody>
</table>

*Subgroup data not available.

AJCC, American Joint Committee on Cancer; em dash, not calculable.
Cumulative local recurrence rates according to clinical stage
The cumulative local recurrence was 5.1% (2.7–9.2%), 17.6% (12.5–24.4%) and 37.2% (25.5–52%) at 1, 5 and 10 years of follow-up for pT1 disease, respectively. There were 3.2% (0.5–20.8%) at 1 year and 29.9% (14.4–55.4%) at 5 and 10 years for pT2 disease. Cumulative local recurrence rate was higher for T3 disease that is, 9.1% (1.3–49.2%) at 1 year and 45.5% (19.3–82.1%) at 5 years. The local recurrence rate of subgroups by clinical stage is shown in Table 2. There was no statistically significant difference in the cumulative rate of local recurrence between different clinical stages of disease (p=0.28, logrank test). The K-M curves showing comparative local recurrence curves for cT1, cT2 and cT3 disease are shown in Figure 2.

Cumulative local recurrence rates according to pathological stage
The cumulative rate of local recurrence was 5.8% (3.1–10.8%), 18.7% (12.9–26.8%) and 37.1% (24.8–52.8%) at 1, 5 and 10 years of follow-up for pT1 disease, respectively. There were 3.2% (0.5–20.8%) at 1 year and 29.9% (14.4–55.4%) at 5 and 10 years for pT2 tumours. There were only 12 cases of pT3 disease and 2 recurrences (n=2), which prevented significance in calculation of recurrence. The pTis tumours showed 0%, 12.4% (4.8–29.7%) and 37.4 (15.3–73.4%) recurrence at 1, 5 and 10 years. The local recurrence rate of subgroups of pathological stages is shown in Table 3. However, there were no statistically significant difference in cumulative rate of local recurrence between eyes with different pathological stages of disease (logrank, p=0.92). The K-M curves showing comparative local recurrence rates for pT1, pT2 and pT3 is shown in Figure 3.

On multivariable Cox proportional hazards analysis (Table 4), eyes with T2 and T3 disease were seen to have more than twice the risk of local recurrence compared to eyes with T1 disease. However, the increased risk of recurrence was statistically significant only for T3 disease (HR=8.06, 95% CI 1.55 to 41.67, p=0.013). No other factors such as tumour ulceration, plica and caruncle involvement, presence of invasive melanoma and tumour thickness reached statistical significance for increased risk of local recurrence (Table 4).

Survival
We have recently published the cumulative mortality rates from the same data set. That research demonstrated the predictive value of AJCC staging for metastasis-related mortality.

DISCUSSION
Herein, we present the results of the first, large, multicentre, international, internet-based registry study on conjunctival melanoma. The local recurrence rate was 19.1% at a median follow-up of 3.6 years (43 months). Overall cumulative rates of local recurrence were found to be progressive at 5.4% at 1 year, 19.3% at 5 years and 36.9% at 10 years of follow-up. The eighth edition of the AJCC clinical staging was predictive of local recurrence in that eyes with T3 disease had more than twice the risk of local recurrence compared to eyes with T1 disease (p=0.013). Herein, we found tumour thickness, plica and/or caruncle involvement and tumour ulceration were not associated with increased risk of local recurrence. Upon spread, nodal involvement was less commonly reported than systemic metastasis.

In review of the literature on conjunctival melanoma, the mean age at diagnosis for conjunctival melanoma varies between 54 and 67 years, and tends to be lower in Asian and African populations. In our study group, the mean age was 60 years and with no pediatric patients. Like most studies, ours revealed no sex predilection. That said, both male and female preponderance has been reported. Conjunctival melanoma has been reported to arise from acquired melanosis in 26–93% cases. In our study, acquired melanosis was noted in 32%. Most of the tumours reported in this registry were pigmented (69%) and nodular (72%) consistent with prior reports. The orbital exenteration rates in the past 4 decades have ranged between 8% and 50%, in our study underwent an incisional biopsy, it is worth noting.
mentioning that incisional biopsies have been associated with increased risk of metastasis.\textsuperscript{12} \textsuperscript{14} Clearly, subtotal excisions lead to a haemorrhagic, scarred tumour bed that is more difficult to define subsequent surgical margins. As seen with conjunctival squamous carcinoma, it is reasonable to assume that treatment of a surgically altered conjunctival melanoma tumour bed is less likely to be curative.\textsuperscript{10}

Local recurrence in our study was reported to occur in 19% of patients as compared to reports ranging from 11% to 69% in published studies.\textsuperscript{12} \textsuperscript{13} \textsuperscript{15} \textsuperscript{16} \textsuperscript{30} \textsuperscript{34} \textsuperscript{35} \textsuperscript{41} \textsuperscript{42} A few studies have documented the median time to local recurrence as 11–17 months.\textsuperscript{13} \textsuperscript{42} \textsuperscript{43} Comparatively, in our study, median local recurrence time was 13 months.

The cumulative 5-year and 10-year local recurrence data range from 26% to 51% and 51% to 60%, respectively, from single-centre studies.\textsuperscript{13} \textsuperscript{42} \textsuperscript{43} Our multicentre data revealed cumulative 5-year local recurrence rate to be 19% and 10-year rate at 37%. Our cumulative recurrence rates were comparable for various cT and pT-categories, implying that clinical AJCC staging is as useful as pathological staging for gauging local recurrence risk.

Multivariate Cox proportional hazards analysis revealed that higher clinical T-staging was the only factor predictive of local recurrence in our study.\textsuperscript{16} \textsuperscript{41} Unlike prior reports, we found that tumour thickness, ulceration, plica and caruncle involvement did not significantly influence local recurrence rates (table 4).\textsuperscript{1} \textsuperscript{15} \textsuperscript{16} \textsuperscript{32} \textsuperscript{34} \textsuperscript{38} \textsuperscript{41}

In our study, there was no difference in local recurrence rates in patients who underwent wide excision alone (19.8%) compared to excision with cryotherapy (21.3%, \textit{p}=0.70). Esmaeli \textit{et al} reported similar outcomes albeit in a smaller sample.\textsuperscript{42} In contrast to reported literature, administration of adjuvant therapy (cryotherapy, plaque brachytherapy or topical chemotherapy) did not significantly alter local recurrence rates (\textit{p}=0.32).\textsuperscript{12} \textsuperscript{16} \textsuperscript{41} This finding supports etiological theories that include therapeutic miss of non-pigmented tumour, surgical tumour transplantation and that second primary tumours are arising from conjunctiva at risk.

This finding also supports the concept that conjunctival melanoma is a multicentric disease and recurrences may be second tumours arising from other foci of clinically undetected in situ, sine pigmento or microinvasive melanoma. In addition, the possibility of adjunctive therapy being biased towards unfavourable tumours cannot be determined.\textsuperscript{44} \textsuperscript{45}

In this study, data collection was subjective to each centre’s specific methods of diagnosis and treatment. There is predominance of early AJCC-staged tumours which likely reflects the patient distribution typically presenting to these centres. This study includes a large number of conjunctival melanoma patients from multiple, international subspeciality eye cancer centres. Thus, this research provides a unique perspective of worldwide care, its risks and the potential benefits of current treatment.

In conclusion, this study suggests that AJCC T-staging can be used to predict local tumour control after treatment. It showed that within a decade of treatment of conjunctival melanomas, the incidence of recurrence progressively increased despite subspecialty management. Multicentre data-sharing was used to reveal critical information on local recurrence of conjunctival melanoma.

### Table 4 Cox proportional hazards model for predicting local recurrence

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. patients (%)</th>
<th>Interval</th>
<th>Univariate analysis</th>
<th>Multivariable analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>HR</td>
<td>CI</td>
</tr>
<tr>
<td>Age</td>
<td>288 (100)</td>
<td>1-year increment</td>
<td>1.02</td>
<td>1.00 to 1.04</td>
</tr>
<tr>
<td>Male</td>
<td>147 (51)</td>
<td>Versus female</td>
<td>0.97</td>
<td>0.53 to 1.63</td>
</tr>
<tr>
<td>Ulceration ( (n=143) )</td>
<td>14 (10)</td>
<td>Versus no ulceration</td>
<td>1.46</td>
<td>0.80 to 2.71</td>
</tr>
<tr>
<td>Plica invovled ( (n=287) )</td>
<td>31 (11)</td>
<td>Versus no involvement</td>
<td>0.94</td>
<td>0.80 to 1.00</td>
</tr>
<tr>
<td>Caruncle involved ( (n=288) )</td>
<td>32 (11)</td>
<td>Versus no involvement</td>
<td>0.81</td>
<td>0.60 to 1.16</td>
</tr>
<tr>
<td>Tumour stage ( (cT2) )</td>
<td>34</td>
<td>Versus T1</td>
<td>0.99</td>
<td>0.64 to 1.53</td>
</tr>
<tr>
<td>Tumour Stage ( (cT3) )</td>
<td>15</td>
<td>Versus T1</td>
<td>1.36*</td>
<td>1.07 to 1.70</td>
</tr>
<tr>
<td>Tumour stage ( (Tx) )</td>
<td>21</td>
<td>Versus T1</td>
<td>1.89</td>
<td>0.57 to 6.19</td>
</tr>
<tr>
<td>Invasive melanoma ( (n=288) )</td>
<td>219 (76)</td>
<td>Versus no invasion</td>
<td>1.01</td>
<td>0.68 to 1.49</td>
</tr>
<tr>
<td>Tumour thickness ( (n=201) )</td>
<td>201 (70)</td>
<td>1 mm increment</td>
<td>1.00</td>
<td>0.93 to 1.17</td>
</tr>
</tbody>
</table>

\( ^*  p<0.05 \)
\( ^**  p<0.01 \)
\( \text{HR} \), hazard ratio; CI, confidence interval.

Twitter https://twitter.com/paulfingermd.

Acknowledgements Yuliya Gavrylyuk IMG MHA, Princess Margaret Cancer Centre, Toronto, Ontario, Canada, assisted with multicentre institutional review board, ethics committee, privacy and other contractual relationships. Dr Sabyasachi Sengupta, Sengupta Research Academy, Maharashtra, India, assisted with statistics and manuscript revisions. They were compensated for their work.


Contributors All of the authors participated in obtaining Internal Review Board and ethics approvals from their local institutions. They entered anonymised data from their local patients. They were sent the original manuscript for critical review, revision and approval.

Funding The Myrna and John Daniels Charitable Trust, the Paul Finger Fund at Princess Margaret Cancer Center and The Eye Cancer Foundation provided monetary support to the Princess Margaret Cancer Centre’s Health Informatics Research Program, which has participated in the design, construction and maintenance of this data registry for conjunctival melanoma. Dr Puneet Jain received an ophthalmic oncology fellowship grant from The Eye Cancer Foundation (http://eyecancercure.com).

Competing interests None declared.
Patient consent for publication Not required.

Provenance and peer review statement Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplemental information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.

See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID

Paul T Finger http://orcid.org/0000-0002-8111-3896

REFERENCES